Search peptides, terms, sources/
Research source · 2026

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
About 5,500 adults with obesity and established cardiovascular disease, chronic kidney disease or cardiovascular risk factors
Sample size
about 5500
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Sponsor-funded (Boehringer Ingelheim). Designed to test non-inferiority for cardiovascular events, not to show a cardiovascular benefit. Abstract read via Europe PMC; full text not read.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.